Janus Henderson Group PLC lessened its holdings in Senseonics Holdings Inc (NYSEAMERICAN:SENS) by 99.0% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 17,463 shares of the company’s stock after selling 1,755,601 shares during the period. Janus Henderson Group PLC’s holdings in Senseonics were worth $36,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors have also made changes to their positions in the company. Daiwa Securities Group Inc. lifted its stake in shares of Senseonics by 20.0% in the 2nd quarter. Daiwa Securities Group Inc. now owns 150,000 shares of the company’s stock valued at $306,000 after purchasing an additional 25,000 shares during the last quarter. Raymond James Trust N.A. lifted its stake in Senseonics by 44.9% during the 2nd quarter. Raymond James Trust N.A. now owns 71,000 shares of the company’s stock worth $145,000 after acquiring an additional 22,000 shares in the last quarter. Canton Hathaway LLC lifted its stake in Senseonics by 48.1% during the 2nd quarter. Canton Hathaway LLC now owns 99,800 shares of the company’s stock worth $204,000 after acquiring an additional 32,400 shares in the last quarter. Marshall Wace North America L.P. acquired a new position in Senseonics during the 1st quarter worth about $118,000. Finally, Marshall Wace LLP acquired a new position in Senseonics during the 1st quarter worth about $272,000. 30.66% of the stock is currently owned by institutional investors and hedge funds.
SENS opened at $1.03 on Thursday. Senseonics Holdings Inc has a 12-month low of $0.98 and a 12-month high of $4.89.
SENS has been the topic of several research reports. BTIG Research reissued a “buy” rating and set a $2.00 target price on shares of Senseonics in a research note on Sunday, August 11th. Raymond James lowered Senseonics from an “outperform” rating to a “market perform” rating in a research note on Friday, July 5th. Finally, Zacks Investment Research lowered Senseonics from a “hold” rating to a “sell” rating in a research note on Saturday, May 11th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and one has assigned a buy rating to the company’s stock. Senseonics presently has an average rating of “Hold” and an average price target of $2.00.
Senseonics Holdings, Inc, a medical technology company, designs, develops, and commercializes continuous glucose monitoring (CGM) systems for people with diabetes primarily in Europe. Its products include Eversense and Eversense XL, which are implantable CGM systems that is designed to continually and accurately measure glucose levels in people with diabetes for a period of up to 90 and 180 days.
Recommended Story: Short Selling Stocks and Day Traders
Receive News & Ratings for Senseonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics and related companies with MarketBeat.com's FREE daily email newsletter.